The Involvement of T Cells and Their Cytokines in Scleroderma (Systemic Sclerosis)—Second Edition

Dear Colleagues,

Despite being among the less common autoimmune rheumatic diseases, systemic sclerosis (SSc) is the most complex, leading to tremendous suffering, disability and substantial mortality. Unfortunately, the therapeutic toolbox for SSc patients is limited, for the most part, to symptomatic rather than curative or preventive medications. Thus, the need to enhance understanding of the basic immune mechanisms underlying SSc is imperative. In this regard, based on early research as well as a plethora of recent studies, a variety of T-cell subsets, including classical major histocompatibility (MHC)-restricted CD8+ and CD4+ T cells, (e.g., regulatory T cells, cytotoxic CD4+ T cells and follicular helper T cells), as well as nonclassical MHC-restricted NKT cells, gamma/delta T cells and innate lymphoid cells, play important roles during the initiation and progression of this devastating disease. Breakthrough studies have shown that in certain cases, pathogenic T cells in SSc may have been instigated by a response to tumor-derived autoantigens. In a plausible scenario, such antigen-activated T cells may drive a pathogenic response by acquiring effector functions, e.g., help for B cells producing disease-related autoantibodies, cytotoxicity against endothelial cells and the downstream elaboration of pathogenic pro-fibrotic cytokines. These effector responses may constitute important mechanisms driving the vasculopathy and widespread fibrotic phenotype underlying systemic sclerosis. The ever-expanding evidence supporting the crucial role of T cells in SSc indicates a crucial imperative to further underpin the mechanisms governing their involvement in the disease, with a view to creating novel preventive and curative therapeutic approaches.

The goal of this Special Issue is to provide a platform to fulfill this goal. Thus, for publication, we will review papers addressing all multifaceted aspects of how T cells and their cytokines participate in the various aspects of SSc. Original studies involving both human patients and animal models are welcome.

Prof. Dr. Ilan Bank
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer
• oncogene
• kinase inhibitors
• tumor drug resistance
• signal transduction
• survival
• cell reprogramming
• target therapy
• cancer heterogeneity
• biomarkers

• The Involvement of T Cells and Their Cytokines in Scleroderma (Systemic Sclerosis) in Cells (2 articles)